nivolumab,ipilimumab,cabozantinib
bms,exelixis
['ipilimumab', 'nivo', 'cabozantinib', 'nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic313']
phase 3 study of cabozantinib in combination with nivolumab and ipilimumab in previously untreated advanced #rcc of imdc intermediate or poor risk (#cosmic313). presented by . #esmo22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology